Screener
Ionis Pharmaceuticals IONS Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 98.2%-0.7pp | 98.4%-0.2pp | 98.3%-0.1pp | 98.8%+0.1pp | 98.9%+0.3pp | |
| Operating margin | -68%-39.8pp | -33.3%+32.6pp | -40.4%+26.9pp | -28.8%+17.4pp | -28.2%+16.6pp | |
| Net margin | -64.7%-36.2pp | -30.9%+33.0pp | -40.4%+24.0pp | -26.5%+18.2pp | -28.4%+16.6pp | |
| Returns | ||||||
| Return on equity | -105.5%-45.6pp | -67.6%+51.0pp | -70.8%+22.3pp | -40%+33.3pp | -59.9%+45.8pp | |
| Return on invested capital | -80.3%-39.6pp | -51%+127pp | -24.2%+91.4pp | -32.4%+101pp | -40.7%+178pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×0.0× | 0.3×+0.1× | 0.3×+0.1× | 0.3×0.0× | 0.3×0.0× | |
| Liquidity | ||||||
| Current ratio | 7.9×+5.0× | 4.1×-5.6× | 3.8×-4.6× | 2.8×-6.1× | 2.9×-4.7× | |
| Leverage | ||||||
| Debt-to-equity | 0.6×-0.7× | 1.4×+1.1× | 5×+4.7× | 1.4×+1.1× | 1.3×+0.5× | |
| Per Share | ||||||
| Book value per share | $2.66-23.3% | $2.98-0.6% | $3.06-22.3% | $3.87-13.2% | $3.46+91.8% | |
| Valuation | ||||||
| Market capitalization | $9.01B+38.9% | $12.4B+159% | $12.81B+132% | $10.43B+78.3% | $6.31B-9.0% | |
| Price / sales | 10.3×+3.4× | 11.7×+5.0× | 13.6×+5.7× | 10.8×+3.5× | 6.7×-1.8× | |
| Price / book | 20.5×+10.2× | 25.2×+15.2× | 26.2×+16.8× | 16.9×+8.0× | 10×-16.3× |
FAQ
- What are Ionis Pharmaceuticals's profit margins?
- Ionis Pharmaceuticals (IONS) runs a 98.2% gross margin and a -68.0% operating margin, with a -64.7% net margin.
- Where do Ionis Pharmaceuticals's ratios come from?
- Every ratio is computed from Ionis Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
